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Abstract
INJECTION DRUG USE AMONG WEST
VIRGINIA MEDICAID BENEFICIARIES:
AN ANALYSIS OF HEALTH OUTCOMES,
SERVICE UTILIZATION, AND COST
Michael J. Cima

In the United States, injection drug use is a serious public health concern associated with
an array of negative health outcomes and substantial financial consequences for systems
of care. The purpose of this study was to characterize a statewide sample of Medicaid
insured persons who inject drugs in terms of health outcomes, service utilization and cost.
A cross-sectional, retrospective analysis of West Virginia Medicaid claims data between
2014 and 2016 was conducted. Between 2014 and 2016, 5,082 West Virginia Medicaid
beneficiaries amassed 14,414 service visits, among which inpatient, emergency room,
and mental health and substance abuse were the most common. Drug poisonings
(n=5,077), soft-tissue infections (n=4,127) and other infectious diseases (n=2,141) were
the most common clinical conditions within this sample. Medicaid claims data were not
a suitable proxy for state surveillance data as it pertains to new cases of Hepatitis B,
Hepatitis C, HIV and heroin overdoses. Ordinal logistic regression results indicate that
infectious diseases like endocarditis and soft-tissue infections are associated with
increased service utilization. Similarly, multiple regression models show increased cost
among individuals with HIV, endocarditis, and Hepatitis B. Preventative services, e.g.
syringe exchange programs, are important tools to reducing the spread of infectious
diseases, and thereby decrease frequent service utilization and cost among injection drug
users.
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CHAPTER 1: INTRODUCTION

Persons who inject drugs (PWID) are subject to a myriad of adverse health outcomes,
including overdose, withdrawal, viral hepatitis, human immunodeficiency virus (HIV),
endocarditis, and other soft tissue infections. (Alter & Moyer, 1998; Binswanger, Kral,
Bluthenthal, Rybold, & Edlin, 2000; CDC, 2016; Rudd, Seth, David, & Scholl, 2016) Recent
nationwide increases in opioid overdoses, acute hepatitis C viral infection (HCV), and an HIV
outbreak among PWID emphasize the urgency of the injection drug use (IDU) epidemic in the
United States (US). (Conrad, Bradley, Broz, Buddha, Chapman, Galang, Hillman, Hon, Hoover,
Patel, Perez, Peters, Pontones, Roseberry, Sandoval, Shields, Walthall, Waterhouse, Weidle, Wu,
& Duwve, 2015; Rudd, Aleshire, Zibbell, & Gladden, 2016; Zibbell, Iqbal, Patel, Suryaprasad,
Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, & Holtzman, 2015) Between 2002
and 2013, the United States heroin overdose death rate more than tripled, from 0.7 to 2.7 per
100,000 people. (Rudd, Seth, et al., 2016) Concurrently, the leading infectious disease killer in
HCV infection increased throughout the US, with the most notable increases occurring among
PWID in rural states including Kentucky and West Virginia (WV) located in central Appalachia.
(Ly, Hughes, Jiles, & Holmberg, 2016; Zibbell, Iqbal, Patel, Suryaprasad, Sanders, MooreMoravian, Serrecchia, Blankenship, Ward, & Holtzman, 2015) In 2015, the Indiana State
Department of Health reported a 181 case outbreak of HIV in a rural community where the
sharing of injection equipment was a contributing factor in 92% of reported cases resulting in
92% of persons coinfected with HCV. (Peters et al., 2016) Additionally, invasive bacterial
infections like endocarditis and other soft tissue infections resulting from direct injection into the
skin or muscle continue to be one of the most common recurring problems among PWID, and is
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costly to healthcare institutions and insurers. (Binswanger et al., 2000; Fleischauer, Ruhl, Rhea,
& Barnes, 2017; Tookes, Diaz, Li, Khalid, & Doblecki-Lewis, 2015)
While adverse health outcomes related to IDU have increased throughout the US, studies
indicate nonurban and rural areas have been disproportionately impacted over the past ten years.
(Des Jarlais et al., 2015; Suryaprasad et al., 2014; Zibbell, Iqbal, Patel, Suryaprasad, Sanders,
Moore-Moravian, Serrecchia, Blankenship, Ward, & Holtzman, 2015) Rural Appalachia, in
particular, has experienced the most pronounced increases in HCV, HIV, and overdoses among
PWID. A recent study, ranking US counties in terms of vulnerability to the spread of IDU related
HCV and HIV identified the most vulnerable counties were largely rural and in the Appalachian
region. (Van Handel et al., 2016) Highly effective and cost containing public health interventions
to counter IDU associated events have been identified in both rural and urban areas of the world,
including syringe and injection equipment exchange programs (SEP). (Kwon, Iversen, Maher,
Law, & Wilson, 2009; D. Wilson, Taaffe, Fraser-Hurt, & Gorgens, 2014; D. P. Wilson, Donald,
Shattock, Wilson, & Fraser-Hurt, 2015)
SEPs reduce IDU health risks via a harm reduction approach, without the explicit primary
objective of IDU cessation. (Bastos & Strathdee, 2000; Kwon et al., 2009; Vickerman et al.,
2006; D. P. Wilson et al., 2015) Nonetheless, multiple studies identified decreasing incidence of
HIV and HCV in locations with SEP and increases in locations without SEPs. (D. P. Wilson et
al., 2015) SEPs offer a range of services which may include education, counseling, STI testing,
distribution of condoms, legal services, and opioid substitution treatment. Some of these
services, e.g. peer based education interventions, are also effective in reducing IDU risk
behaviors, such as sharing injection equipment. (Mackesy-Amiti et al., 2013)Compared to other
prevention strategies, SEPs are relatively inexpensive to implement and sustain, with an
2

estimated cost ranging between $23-$71 (US) per person, per visit depending on location and
services offered with the return on investment of approximately $5 saved to every $1 spent.
(Kwon et al., 2009; D. Wilson et al., 2014; D. P. Wilson et al., 2015)This return on investment
was based on the dollars saved for preventing at least one infection such as HIV, HCV, and/or
other soft tissue infections compared to dollars spent on equipment and services.
While SEPs are demonstrably effective, these services have not diffused widely in the
US, either rural or urban. According to the results of a recent, nationwide study of SEPs from
various regions of the US, fewer SEPs were located in rural (30 SEPs) areas compared to urban
(105 SEPs) areas. (Des Jarlais et al., 2015) Further, half of rural SEPs were categorized as
“small” or “medium”, and exchanged far fewer syringes per program than their urban
counterparts (medians of 55,000 syringes exchanged vs. 146,263 syringes exchanged) In terms
of operating characteristics, rural SEPs report fewer mobile exchanges, more problems with
procuring funding, reaching participants, and fewer full-time personnel. (Des Jarlais et al., 2015)
Additionally, the federal ban on funding components of SEPs persists ("Public Health and
Welfare Act," 1988), thus potentially limiting the availability of services and resources. The lack
of prevention services for PWID in rural areas is an important disparity which not only directly
affects public health, but also increases the amount of money spent on healthcare by insurers,
including Medicaid.
There is an established link between IDU and poverty in wealthy countries. (Crime,
2016) With the expansion of Medicaid, a government subsidized health insurance program,
under the Affordable Care Act (ACA) in 2010, health insurance is more available to millions of
lower income Americans, decreasing uninsured adults. (Blumenthal, Abrams, & Nuzum, 2015)
In states with expanded coverage, individuals with a household income at or below 133% of the
3

federal poverty level (FPL) are eligible for Medicaid. (Blumenthal et al., 2015) Therefore,
Medicaid expansion may result in more PWID receiving coverage. Even prior to Medicaid
expansion, studies have shown that PWID are often covered by Medicaid when eligible.
(Fleischauer et al., 2017; Takahashi, Baernstein, Binswanger, Bradley, & Merrill, 2007; Tookes
et al., 2015) In these studies, Medicaid was billed for a majority of the injection drug-related
services rendered, and these services tended to be more expensive than services for other patients
during the same time. One study estimated the average cost per hospitalization for PWID with
soft-tissue infections, like abscesses and cellulitis, was $4,449 compared to $3,540 for non-IDU
related hospitalizations (US). (Takahashi, Maciejewski, & Bradley, 2010) In another similar
study, costs of treating endocarditis among PWID exceed $50,000, and were billed to Medicaid
for 42% of the time. (Fleischauer et al., 2017)

1.1 Problem Statement
Emergency and other care costs for persons who inject drugs are increasingly covered by
Medicaid expansion and other publicly funded programs. (Tookes et al., 2015) Few studies have
utilized individual level Medicaid data from a rural state to assess care costs and utilization. Use
of Medicaid claims data may provide a unique opportunity to address gaps in knowledge
surrounding service utilization and associated costs within this hard to reach population.
1.2 Conceptual Framework for the Study
Several studies use claims data to investigate various issues related to drug abuse.
(Birnbaum et al., 2011; Dufour et al., 2014; McAdam-Marx, Roland, Cleveland, & Oderda,
2010; Shei et al., 2015; White et al., 2005) The methodology of a majority of these studies
involves retrospectively querying claims databases, using ICD-9 & ICD-10 codes, in order to
4

describe the prevalence and cost of opioid drug abuse among an insured population. As of
October 1, 2015, the United States shifted from ICD-9 to ICD-10 codes. (CDC, 2017) Studies
querying claims databases with ICD codes generally show that the prevalence of opioid abuse
has increased, (Dufour et al., 2014) opioid abusers tend to have more comorbidities, (McAdamMarx et al., 2010; Shei et al., 2015) and costs associated with opioid abuse are significant.
(McAdam-Marx et al., 2010; White et al., 2005) However, the current body of research
surrounding claims data and drug abuse focuses predominantly on prescription opioid abuse,
perpetuating the gap in IDU, which is further exacerbated by a paucity of research with a focus
on rural IDU.
This study builds on the opioid drug foundation using a previously established (Tookes et
al., 2015) methodological framework to focus on the IDU epidemic in a rural US state. ICD-9 &
ICD-10 codes specific to outcomes associated with IDU will be used to define IDU for this
study. Additionally, the ICD codes will serve as a basis for retrospectively querying a Medicaid
claims database. Services, health outcomes, and patient characteristics will be described in terms
of frequency and cost. This project provides an opportunity to develop a more detailed view of
insured PWID.

1.3 Purpose of the Study
The proposed study investigates the public health and economic consequences of the IDU
epidemic as supported by West Virginia Medicaid data. The frequency of injection drug-related
health outcomes, service type, charge, and patient characteristics will be described. Specifically,
this project seeks to identify if Medicaid claims data have utility for investigating issues
experienced by a hard to reach population specifically PWID. Previous studies show that PWID
5

tend to use emergency departments as primary care, and present late during the course of disease.
(Palepu et al., 2001) These issues combined with a previous lack of widespread electronic
medical record utilization has created a challenge in identifying complete data sources for this
population. As Medicaid expansion provides coverage to many lower income persons, an
opportunity to increase knowledge among multiple medically fragile groups presents itself.
(Blumenthal et al., 2015) The proposed study will create a comprehensive profile of a statewide
sample of Medicaid insured PWID, including a description of the most frequent and costly
services accessed, health outcomes related to IDU and sociodemographic characteristics
associated with poor outcomes, frequent service usage, and high cost.

1.4 Specific Aims and Objectives
Aim 1: Determine the efficacy of state Medicaid data as a proxy for disease surveillance data in
estimating the number of drug overdoses and injection drug related infections in WV between
2014 and 2016.
1. Quantify and describe overdoses, and IDU associated infections among WV Medicaid
beneficiaries who received services related to IDU between 2014 and 2016.
2. Compare rates and proportion of overdose and IDU associated infections obtained from
Medicaid claims data to surveillance data.
Aim 2: Examine service utilization and characteristics of WV Medicaid beneficiaries who inject
drugs between 2014 and 2016.
1. Describe the economic, demographic, and service utilization characteristics of WV
Medicaid beneficiaries who received services related to IDU between 2014 and 2016.
6

2. Assess the relationship between frequent service utilization and patient characteristics.
Aim 3: Examine the cost of service utilization of WV Medicaid beneficiaries who inject drugs
between 2014 and 2016.
1. Quantify the total cost of services, the costliest services, and describe the geographic
distribution among PWID and who are covered by Medicaid between 2014 and 2016.
2. Assess the relationship between total costs and patient characteristics and diagnoses.

1.5 Procedures
The sample for the proposed project will be comprised of WV Medicaid beneficiaries
who have received IDU-related services between 2014 and 2016. This date range was chosen
based on the state Medicaid expansion coverage under the ACA began January 1, 2014.
Inclusion in this study will be based on specific criteria to determine whether a person injects
drugs and if they have experienced an outcome related to IDU. ICD-10 codes will serve as the
basis for these criteria. Relevant data elements will be formally requested from the WV
Department of Health and Human Services (DHHR), Bureau for Medical Services (BMS), which
is charged with operating WV Medicaid and maintaining data. The individual level data that
results from the request will not contain any personally identifiable information. Appropriate
analyses will be conducted to accomplish each aim and subsequent objective outlined previously.

1.6 Significance
Without access to sterile injection equipment and other services offered by harm
reduction programs, PWID are more susceptible to adverse health outcomes leading to increased
7

morbidity and mortality. (Grebely & Dore, 2014) Costs associated with providing emergency
and recurring IDU-related services to PWID are substantial, and increasingly billed to Medicaid.
(Takahashi et al., 2007; Tookes et al., 2015) These factors support the need for a shift towards
preventative care and services for PWID. However, harm reduction services are considerably
less common in rural areas, where it has been shown there is a significant need. (Des Jarlais et
al., 2015) West Virginia continues to struggle with the consequences of IDU, and consistently
reports some of the highest rates of overdoses and related infections in the US. (Rudd, Aleshire,
et al., 2016; Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-Moravian, Serrecchia,
Blankenship, Ward, & Holtzman, 2015)
Increasing the knowledge within West Virginia of these issues by creating a
comprehensive profile of Medicaid beneficiaries who inject drugs by assessing and describing
the services received, inclusive of charges, and the geographic distribution of services indicate
where prevention strategies, such as harm reduction, could be most useful. As the predominant
insurer of PWID nationally, Medicaid programs can benefit from this information to identify
avenues for improving healthcare access and containing costs. Additionally, given the paucity of
information available on PWID in rural areas, the proposed project will add valuable information
to the current body of research.

1.7 Limitations
There are limitations to the proposed study. First, this study will use ICD-9 codes to
determine beneficiary IDU status and related adverse health outcomes. Some studies suggest that
using ICD-9 or -10 codes for research could result in the underreporting of certain conditions.
(G. Jones et al., 2012) This may be exacerbated when dealing with complex behaviors like IDU,
8

since it can be difficult to ascertain route of drug use from ICD-9 codes. Another drawback to
this study design is the retrospective, secondary data analysis component using data not
originally collected for research. Because of this, it is not always possible to include all
necessary data elements for the analyses to control for issues like confounding. This study will
only include PWID who are or were insured by Medicaid between 2014 and 2016. Consequently,
PWID who are covered by private insurance or have no insurance coverage will not be included.
Past research suggests that this could include a significant proportion of the total population of
PWID. (CDC, 2015b; Tookes et al., 2015) Not including those who are uninsured or are insured
by plans outside of Medicaid could diminish the generalizability of the proposed study.

1.8 Organization
The proposed study will be organized as four separate chapters to include: an extensive
literature review (Chapter two), methods section (Chapter three), relevant results (Chapter four),
and discussion of and conclusions drawn from results (Chapter five). Chapter two will include a
systematic approach to reviewing the current body of research surrounding drug use among
Medicaid beneficiaries. Chapter three will discuss the methods employed in defining the study
sample, obtaining data, and analyzing data. Chapter four will present the results obtained from
analyses in tables, figures, and paragraph form. Finally, chapter five will elaborate on results,
synthesize appropriate conclusions, and make recommendations for future research.
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CHAPTER 2: LITERATURE REVIEW

The US injection drug use (IDU) epidemic is a public health concern associated with negative
health outcomes and substantial financial consequences for systems of care. Specifically, IDU is
associated with increased overdose deaths, infectious diseases, and cost to healthcare institutions
and government subsidized insurers like Medicaid. (Kwon et al., 2009; Rudd, Aleshire, et al.,
2016; Takahashi et al., 2010; D. P. Wilson et al., 2015; Zibbell, Iqbal, Patel, Suryaprasad,
Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, Holtzman, et al., 2015) This study
seeks to understand the factors associated with the health and financial consequences of IDU
using individual level service of IDUs in the state.

2.1 U.S. Drug Use
Prescription opioid pain relievers and heroin are opioids that are considered the driving
force behind the substantial increase in overdose deaths in the US. Between 1999 and 2015,
overdose (OD) rates for prescription opioids and heroin have nearly quadrupled, resulting in
more than 500,000 deaths. (C. M. Jones, Logan, Gladden, & Bohm, 2015) In 2015 over 50,000
drug overdose deaths (ODD) occurred; 30,000 of which were opioid attributable, marking the
highest annual ODDs in US history and a nearly three-fold increase since 2002. (Rudd, Seth, et
al., 2016) Between 2014 and 2015, states in the North and Southeast census regions experienced
statistically significant (p-value <0.05) increases in ODDs, including: West Virginia (41.5 per
100,000), New Hampshire (34.3 per 100,000), Kentucky (29.9 per 100,000), Ohio (29.9 per
100,000), and Rhode Island (28.2 per 100,000). (CDC National Vital Statistics System, 2016;
Rudd, Seth, et al., 2016) Adults aged 25 to 64 have the highest ODD rates, however, ODDs
increased specifically among 25 to 34 year olds, and men and white, non-Hispanics since 2010.
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(Rudd, Seth, et al., 2016) Also during this time, heroin ODDs increased by more than 20%
nationwide with each census region reporting a statistically significant increase. (CDC National
Vital Statistics System, 2016) Consistent with other drug OD, men between the ages of 25 and
44 had the highest heroin ODs. However, heroin ODD rates are increasing among groups with
historically low rates, such as persons aged 18 to 25 years, women, and persons with higher
income. (CDC, 2015b) These trends for heroin ODs, specifically, contribute to the growing
importance of IDU in the US.
2.2 U.S. IDU
IDU is associated with multiple complications in addition to ODs, including economic
distress, spread of infectious diseases, mental illness, and reduced access to care. (Centers for
Disease & Prevention, 2012; Palepu et al., 2001; Richardson, Wood, Li, & Kerr, 2010) Given the
upward trend of IDU across the US, the effects of these complications could become more
pronounced for not only PWID, but also healthcare institutions and insurers.
2.2.1 Associated Social and Economic Factors
Economic distress, unemployment and decreased social functioning are significant
aspects of IDU. (Richardson et al., 2010) Studies consistently report an inverse association
between IDU and employment, and typically characterize PWID as an impoverished population.
For example, one recent, nationally representative study found a strong association between
unemployment and illicit drug use. (Compton, Gfroerer, Conway, & Finger, 2014) Additionally,
another study reported a poverty rate in excess of 60% for a particular cohort of PWID. (Cooper
et al., 2016).
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Homelessness has long been tied IDU through overlapping risk factors such as poverty,
incarceration, and mental health. (Briggs et al., 2009; Linton, Celentano, Kirk, & Mehta, 2013;
Mizuno et al., 2009) Additionally, evidence supports a temporal relationship between
homelessness and IDU initiation or relapse. One recent study found that among those who had
stopped injecting, homelessness was associated with IDU relapse, regardless of the duration of
homelessness. (Linton et al., 2013) Further, homelessness was also associated with injectionrelated risk behaviors, including needle and cotton sharing, as well as mental illness.
In the US, drug policy seemingly centers on the idea that arrests deter drug-related crimes
and drug use in general. (Friedman et al., 2011) Consequently, the US has one of the highest
rates of drug-related incarcerations compared to similar countries, with 46% of all federal
offenses relating to drug use. (Prisons, 2017) However, evidence from recent studies suggests
that increasing arrests for drug crimes does not decrease drug use, and is costly. One estimate
puts the cost per inmate at over $20,000, which translates to nearly $12 billion to incarcerate
inmates with drug-related offenses. (Warren, Gelb, Horowitz, & Riordan, 2008)
2.2.2 Associated Comorbidities
PWID who share injection equipment with infected persons are at an increased risk for
bloodborne pathogens, including HIV, viral hepatitis, and soft-tissue infections, like cellulitis
and abscesses. In some studies, the estimated prevalence of hepatitis C (HCV), hepatitis B
(HBV), and HIV among IDUs was as high as 77%, 66%, and 21% respectively. (Garfein,
Vlahov, Galai, Doherty, & Nelson, 1996; Spiller et al., 2015; Zibbell, Iqbal, Patel, Suryaprasad,
Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, Holtzman, et al., 2015) HIV/HCV
coinfection is also common among IDUs, with rates found as high as 92%. (Peters et al., 2016;
Platt et al., 2016) In co-infected persons, HCV may transmit more efficiently, including
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increased risk for perinatal transmission by infected mothers. (Platt et al., 2016) Coinfection can
complicate HIV treatment leading to antiretroviral related hepatotoxicity. (Platt et al., 2016;
Shepard, Finelli, & Alter, 2005) Risky behavior engagement, such as unprotected sex, social
issues, including unstable housing, lack of access to care, limited availability of sterile injection
equipment, and decreased availability of treatment programs, and other societal and healthcare
related factors contribute to the spread of infectious diseases. (Altice, Kamarulzaman, Soriano,
Schechter, & Friedland, 2010; Burris & Strathdee, 2006; Centers for Disease & Prevention,
2012; Chander, Himelhoch, & Moore, 2006; Friedland, 2010; Gebo, Keruly, & Moore, 2003;
Regier et al., 1990; Rhodes, Singer, Bourgois, Friedman, & Strathdee, 2005).
In addition to infectious diseases, PWID tend to have higher rates of depression,
personality, and/or anxiety disorders, as well as polysubstance abuse and history of adverse
childhood events, which pose significant obstacles to improving health outcomes. (MackesyAmiti, Donenberg, & Ouellet, 2012, 2014; Sansone, Whitecar, & Wiederman, 2009) One study
reports the prevalence of major mental health disorders at more than one third among PWID.
(Kidorf et al., 2004) In particular, 25% of adults with Schizophrenia have reported illicit drug
use in their lifetime. (Van Dorn, Desmarais, Young, Sellers, & Swartz, 2012) These psychiatric
disorders have been shown to be associated with certain IDU risk behaviors, including injection
equipment sharing with a high number of people, sharing with strangers, and with people known
to be HIV-infected. (Kidorf et al., 2010; Mackesy-Amiti et al., 2014)
2.2.3 Care Access, Utilization, and Economic Impact of IDU
Poor access to healthcare and service utilization is a well-documented problem for
PWID. (Chitwood, McBride, French, & Comerford, 1999; McCoy, Metsch, Chitwood, & Miles,
2001) PWID generally have low access to primary care for a multitude of reasons, including
13

inability to set and keep appointment times. Consequently, PWID may use emergency
departments as their primary source of healthcare, resulting in later disease stage presentation for
care and higher costs. (Fairbairn et al., 2012; French, McGeary, Chitwood, & McCoy, 2000;
Palepu et al., 2001; Solomon, Frank, Vlahov, & Astemborski, 1991) For example, in one
Canadian-based IDU cohort study, 60% of PWID were frequent users of the emergency
department (at least three visits). Among all PWID accessing the emergency department, HIVpositive persons were more likely to be frequent users (adjusted OR 5.4, 95% CI 3.4-8.6), and
have higher costs. (Palepu et al., 2001)
The economic impact of treating IDU related complications can be substantial as it
includes infectious diseases, which are largely preventable with access to sterile to injection
equipment. In addition to serious medical consequences associated with HIV, including
weakened immune system, susceptibility to opportunistic infections, transmissibility, and death,
the price of treating one new case into perpetuity is especially burdensome. Treating one HIV
case costs approximately $38,000 per year, with considerable variation dependent on disease
stage. (Fleishman, Monroe, Voss, Moore, & Gebo, 2016) Further, the most recent available data
estimates the total lifetime cost of treating one case of HIV to be between $253,000 and
$402,000 depending on disease stage. (Farnham et al., 2013) Considering that approximately
9%, or 3,600 new cases of HIV in the US each year identify IDU as risk factor, approximately
$136.8 million are spent on new HIV infections just among PWID. (CDC, 2016)
With more than 60% of HCV cases reporting IDU as a risk factor, the financial
considerations of IDU and HCV is equally important. Until recently, HCV was a chronic
condition that typically lasted for the infected patient’s lifetime. However, with the advent of
direct acting antivirals (DAAs), HCV is curable in a large percentage of people. A drawback to
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these drugs is the price of the regimens. In the US, certain DAA drugs, such as sofosbuvir, cost
as much as $84,000 for a 12-week regimen, or approximately $1,000 per pill. (Rosenthal &
Graham, 2016) The most recent available data indicate more than 2,100 acute HCV diagnoses in
2014, which translates to over $176 million spent on treating HCV among PWID yearly. (CDC,
2014) Moreover, with increasing cure rates comes the possibility of relapse, thus further
exacerbating the financial burden of treating HCV.
Although HBV is vaccine preventable, for persons without vaccination, there still is a
financial burden associated with treatment. One cost analysis reported the range of costs for
treating HBV according to complications and disease stages. (Lee, Veenstra, Iloeje, & Sullivan,
2004) According to this study, the annual cost for treating chronic HBV was $761 per patient;
decompensated cirrhosis because of HBV was $11,459 per patient; liver transplant was $86,552
per patient; transplant follow-up care was $12,560 per patient; and hepatocellular carcinoma was
$7,533 per patient.
Soft-tissue infections and endocarditis are common among PWID who do not have access
to sterile injection equipment. One study reported that a third of PWID were treated for softtissue infections like cellulitis and abscesses. (Binswanger et al., 2000) Hospitalizations among
PWID with soft-tissue infections can result in significant costs with one recent study estimate of
$4,449. (Takahashi et al., 2010) Further, another study reported that over a one-year period,
PWID treated for soft-tissue infections at a single hospital incurred $11.4 million in charges.
(Tookes et al., 2015) Additionally, 41% of these charges were billed to Medicaid, the largest
insurer for this group. (Tookes et al., 2015) Similarly, endocarditis among PWID has increased
over the past decade, with high costs billed predominantly to Medicaid. In a recent study, PWID
presenting to a single hospital incurred over $50,000 per hospitalization for endocarditis, and
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most (42%) were insured by Medicaid. (Fleischauer et al., 2017) Although soft-tissue infections
are acute and readily treatable, the cost of consistently treating PWID is formidable combined
again with late stage presentation for care.
Despite poor primary care utilization among PWID and subsequently higher costs,
effective public health interventions, such as harm reduction can alleviate some negative health
outcomes and reduce costs. Harm reduction refers to strategies aimed at diminishing health risks
associated with behaviors like IDU. (D. P. Wilson et al., 2015) When considering harm reduction
for IDU, syringe exchange programs (SEP) are one of the more common methods employed, and
seek to reduce the spread of bloodborne pathogens and soft-tissue infections. The underlying
function of SEPs involves the distribution of sterile needles, syringes, and injection equipment to
PWID, while collecting and safely discarding used paraphernalia.
SEPs implemented in a variety of locations worldwide and in the US have been effective
in reducing the spread of infectious diseases. (Bastos & Strathdee, 2000; Kwon et al., 2009;
Vickerman et al., 2006; D. P. Wilson et al., 2015) A systematic review conducted by Wodak et al
found 23 studies reported SEPs reduced risk behaviors associated with HIV. (Wodak & Cooney,
2005) In particular, one of those studies reported significant decreases in HIV incidence after the
implementation of a SEP (4% - 1%). (Jarlais et al., 2005) Other studies have found as much as an
80% reduction in HIV, HCV, and other bloodborne pathogen incidence among those began
injecting drugs after the implementation of SEPs. (Somaini et al., 2000)
SEPs are successful in reducing the spread of infections because of the effectiveness in
reducing the sharing of needles and equipment. A number of studies report PWID who also
participate in SEPs are less likely to self-report sharing needles, syringes or injection equipment.
One of those studies found a protective effect of participation in a SEP on sharing behavior
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(aOR= 0.77, 95% CI=0.67-0.88). (Holtzman et al., 2009) Similarly, a separate study found that
participation in a SEP reduced the odds of receptive needle sharing by nearly 60% (OR=0.33
CI=0.23-0.46), lending needles by 45% (OR= 0.55 CI=0.41-0.75), and sharing equipment by
30% (OR= 0.70 CI=0.52-0.95). (Huo & Ouellet, 2007). Another important function of SEPs is
the collection and disposal of used needles or syringes, ensuring the potentially hazardous
materials are discarded appropriately, further reducing sharing behaviors and risk to the general
public. However, relatively few US-based studies have investigated needle return rates at SEPs.
(Ksobiech, 2004) One literature review found that of US-based studies, the overall average
needle return rate was approximately 90%. (Ksobiech, 2004) Although, there was significant
variation between studies (68%-102%). (Paone, Jarlais, Caloir, Clark, & Jose, 1995)
The evidence supporting the effectiveness of SEPs in reducing the spread of bloodborne
pathogens and other infections among PWID is abundant. (Holtzman et al., 2009; Hurley, Jolley,
& Kaldor, 1997; Jarlais et al., 2005; Kwon et al., 2009) In addition, SEPs tend to be a costeffective intervention by averting costs of new infections while costing relatively little to operate.
(D. P. Wilson et al., 2015) According to one estimate, implementing and maintaining a SEP costs
approximately $23-$71 per person accessing services per year. (D. Wilson et al., 2014) Further,
one study found that in addition to significantly reducing HIV incidence, a SEP reported an
approximate $5 saved as a result of infection aversion for every $1 invested in providing
services. (Kwon et al., 2009) Moreover, considering the cost of treating new cases of HIV
(~$136 million per year) and HCV (~$176 million per year) just among PWID, the economic
benefits of having optimal coverage of SEP could be profound. (Farnham et al., 2013; Rosenthal
& Graham, 2016) This is especially true for economically depressed, rural regions of the US
where IDU is becoming more of an issue. (Des Jarlais et al., 2015)
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IDU is a highly stigmatized behavior, and significant barriers prevent many PWID from
accessing treatment and harm reduction services. Notable barriers include availability of
services, distance from services, fear of police, and stigmatization among others. (Allen, Ruiz, &
Jones, 2016; Beletsky et al., 2014) In one study, police encounters were an important barrier to
accessing a SEP with 52% of clients having been stopped by police, 10% reporting syringe
confiscation, resulting in persons police encounters becoming less likely to access the SEP
(adjusted OR= 0.59; CI=0.40-0.89). (Beletsky et al., 2014) Availability of harm reduction
services in rural areas is also of concern because of the relatively few programs in operation.
(Des Jarlais et al., 2015) Addressing these barriers could not only improve health outcomes
among PWID, but also reduce spending associated with increased utilization of emergency
services and treating new bloodborne infections.
With the passing of the Affordable Care Act in 2010 came a large-scale expansion of
Medicaid to include more lower-income Americans. (Blumenthal et al., 2015) Medicaid is a
government subsidized health insurance program, administered at the state-level, which provides
coverage to low-income adults, children, and pregnant women among others. Second only to
employer-based insurance, Medicaid is one of the largest insurers of Americans, covering
approximately 20% of the population. (Foundation, 2015) Although there is no estimate of the
number of PWID covered by Medicaid, indications are that it is a large proportion. A number of
studies conducted on an array of topics related to IDU have shown that Medicaid is often the
predominant insurer among PWID. (C. M. Jones et al., 2015; Knowlton et al., 2001; Takahashi et
al., 2010; Tookes et al., 2015; Yehia et al., 2014) The proportion of PWID covered by Medicaid
varied between studies, with the largest reported at approximately 60%. (Yehia et al., 2014) One
particular study investigated health insurance status among persons with HIV were more likely
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to be insured by Medicaid (60%) with Medicare covering 19%. (Yehia et al., 2014) The CDC
estimates that 5% of persons who overdosed on injected heroin were Medicaid covered and this
was the only consistent insurance coverage. (CDC National Vital Statistics System, 2016)
2.3 IDU and Rurality
2.3.1 IDU in Rural US
Rural states are disproportionately impacted with higher rates of opioid abuse.
Traditionally considered an urban problem, rural drug abuse has increased over the past two
decades. (Dombrowski, Crawford, Khan, & Tyler, 2016; Gfroerer, Larson, & Colliver, 2007;
Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward,
Holtzman, et al., 2015) The most significantly impacted states are those in the rural, central
Appalachian region which contains states with some of the highest age-adjusted rates of ODDs.
(Rudd, Seth, et al., 2016) Although not widely reported, studies have identified important social
and demographic differences between rural and urban drug abusers, including: age of drug use
initiation is younger among rural drug users; persons tend to be white and non-Hispanic; and
have different initiation patterns for IDU (Young, Havens, & Leukefeld, 2012) (Paulozzi, 2012)
(Young et al., 2012) Heroin overdoses have permeated rural regions. Fentanyl encounters,
specifically, are on the rise in the central Appalachian region. (CDC, 2015a) Fentanyl, a
synthetic opioid pain reliever that can be up to 100 times stronger than morphine, is a common
drug of choice and manufactured in a method which increases the probability of OD. (Algren et
al., 2013) Between 2014 and 2015, fentanyl overdose death rates increased by 72%, resulting in
9,500 deaths nationwide. (Rudd, Seth, et al., 2016)
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2.3.2 Social and Economic Factors in Rural US
Compared to the rest of the US, the rural, central Appalachian region struggles with
unemployment and economic hardship. As of 2017, the unemployment rates for certain central
Appalachian states, like West Virginia (4.9) and Kentucky (5.0), were among the worst in the
nation (4.5). In 2015 median household income was significantly lower than the national
average ($33,000 v. $53,000); and nearly 25% of central Appalachians were living in poverty
compared to the 14% national average. (Pollard & Jacobsen, 2017)The Appalachian Regional
Commission (ARC) created an index, using unemployment rates, poverty rates, and income, to
assess the economic status of Appalachian counties. According to this index, in 2016, the
majority of the 84 Appalachian counties classified as ‘economically distressed’ were in the
central Appalachian region. These economic characteristics factor into the current opioid
epidemic plaguing this area. Studies have drawn a connection between economic hardship and
substance abuse within Appalachia and abroad. (Compton et al., 2014; Richardson et al., 2010)
The situation in post-recession Appalachia is comparable to the collapse of the Soviet Union, the
other region in the world which has faced increased injection drug use following economic
hardships. Following the collapse, former Soviet Union nations experienced increases in
unemployment, depression, suicide, and substance abuse. (Atlani, Carael, Brunet, Frasca, &
Chaika, 2000; McKee, 2005)
2.3.3 IDU Associated Infectious Diseases: Rural v. Urban
IDU and infectious diseases are increasing in importance in rural areas with increased
rates of HCV and HBV. (Suryaprasad et al., 2014) Between 2006 and 2012, there was a 364%
increase in the number of acute cases of HCV among people 30 and younger within central
Appalachia, which includes Kentucky, West Virginia, Tennessee, and Virginia. Among these
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cases, 73% indicated IDU as a risk factor. (Zibbell, Iqbal, Patel, Suryaprasad, Sanders, MooreMoravian, Serrecchia, Blankenship, Ward, Holtzman, et al., 2015) HBV increased in the same
states while remaining stable throughout the rest of the US. (Harris et al., 2016) Between 2006
and 2013, there was a 114% increase in acute HBV cases reported from West Virginia,
Kentucky, and Tennessee, with a majority indicating IDU. (Harris et al., 2016) HIV infections
among rural PWID has also been a significant issue recently. In 2015, an HIV outbreak of IDUs
in rural Indiana led to 135 new infections with 80% reporting a history of IDU. (Conrad,
Bradley, Broz, Buddha, Chapman, Galang, Hillman, Hon, Hoover, Patel, Perez, Peters,
Pontones, Roseberry, Sandoval, Shields, Walthall, Waterhouse, Weidle, Wu, Duwve, et al.,
2015)
In 2016, the CDC conducted a nationwide assessment of HCV/HIV risk among IDUs at
the county level. (Van Handel et al., 2016) This study revealed the majority of counties at the
highest risk for increased rates of IDU-related HCV and HIV were rural and concentrated in the
central Appalachian region. Additionally, half of WV counties were among the most vulnerable
to the spread of HCV and HIV among PWID, including two of the top ten most vulnerable
counties. (Van Handel et al., 2016)
2.3.4 Care Access: Rural v. Urban
In general, there are significant disparities in health care access between rural and urban
areas of the US. (Douthit, Kiv, Dwolatzky, & Biswas, 2015) Certain barriers affecting health
care access are specific to rural regions, and include cultural and financial constraints, scarcity of
services, lack of trained physicians, insufficient public transport, and poor availability of
broadband internet services. (Douthit et al., 2015) Consequently, rural inhabitants tend to be in
poorer health and have less access to a regular physician compared to their urban counterparts.
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(Douthit et al., 2015) Similar disparities exist for rural and urban PWID, understated by the
availability of access to harm reduction services.
As of 2014, over 200 SEPs were in operation across the US. (Des Jarlais et al., 2015)
However, according to a recent report, significantly fewer SEPs and harm reduction services
were available outside of urban centers. (Des Jarlais et al., 2015) Additionally, rurally based
SEPs exchanged far fewer needles, had smaller budgets, and were more likely to report barriers
to optimal service delivery, including lack of full-time or paid staff, funding, and problems
recruiting participants. (Des Jarlais et al., 2015) With increased heroin overdoses, a recent
outbreak of HIV among PWID in a rural community, and a reported increase in vulnerability to
the spread of HIV and HCV among PWID in rural counties, it is apparent there is a need for
more SEPs and harm reduction services in rural areas of the US. (Conrad, Bradley, Broz,
Buddha, Chapman, Galang, Hillman, Hon, Hoover, Patel, Perez, Peters, Pontones, Roseberry,
Sandoval, Shields, Walthall, Waterhouse, Weidle, Wu, Duwve, et al., 2015; Rudd, Seth, et al.,
2016; Van Handel et al., 2016)
2.4 West Virginia
West Virginia (WV) is a rural state in central Appalachian with a decreasing population
currently at 1.8 million. In terms of sociodemographic characteristics, WV is a predominantly
white and non-Hispanic (93.6%) state that has an unemployment rate of 6% and almost 1 in 5
persons living in poverty. (Statistics, 2017; "United States Census Bureau: Statistical Abstract of
the United States: 2011 (130th Edition)," 2011).
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2.4.1 Drug Overdoses
Compared to the rest of the US, West Virginia has the highest opioid ODD rate at 41.5
deaths per 100,000 people with Kentucky as the next closest at 34.3 deaths per 100,000. (CDC
National Vital Statistics System, 2016) The WV age-adjusted ODD rate has increased 10-fold
since 1999, and by 16.9% since 2014. Among states reporting information on prescription and
heroin ODDs, WV ranks as one of the highest nationally, with rates of 19.8 deaths and 11.8
deaths, respectively, per 100,000 people. (CDC National Vital Statistics System, 2016)
2.4.2 IDU Associated Infectious Diseases
As of 2014, WV has the second highest rate of HCV and the highest rate of HBV in the
US at 3.4 per 100,000 and 10.1 per 100,000 respectively with additional studies showing a
continuing increase among IDUs. (CDC, 2014; Harris et al., 2016; Van Handel et al., 2016;
Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward,
Holtzman, et al., 2015) Notably, the HBV rate is nearly triple that of the next highest state,
Kentucky, which reported 3.7 cases per 100,000 people in 2014. (CDC, 2014) Despite these
disproportionately high rates of HCV and HBV, state HIV surveillance data shows one of the
lowest rates of new HIV infections at 4.7 cases per 100,000 people. (CDC, 2016) However,
considering the upward trend of HCV and HBV rates among PWID, increases in HIV rates may
follow as a result of overlapping risk factors.
2.4.3 Care access
Access to care, especially infectious disease care is limited to the larger cities. Further,
many of the barriers that inhibit the utilization of care and services in rural regions of the US are
likely to affect similar areas in WV. Consequently, high-risk populations especially, like PWID,
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have fewer options for healthcare, and may have worse outcomes. One way the state Department
of Health and Human Resources (DHHR) attempts to combat these issues is through bolstering
infectious disease testing. According to a recent health advisory, the WV DHHR recommended
screening for HIV, HCV, and HBV routinely and simultaneously, reporting clusters of HIV
within 24 hours, and providing screening and counseling. Specifically, the WV DHHR
recommends testing and counseling be conducted in opioid substitution therapy programs (e.g.
methadone), buprenorphine-prescribing facilities, drug rehabilitation or detoxification programs,
mental health service providers for substance use disorder, harm reduction and syringe service
programs, emergency departments and in-patient settings, jails and prisons. Although screening
is important, investing in and expanding coverage of interventions specific to PWID, like harm
reduction, could reduce the impact of IDU in West Virginia. (DHHR, 2017)
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CHAPTER 3: METHODS

3.1 Participants
Secondary data from Medicaid-insured individuals residing in West Virginia diagnosed
with conditions related to injection drug use (IDU) between the fiscal years 2014 and 2016 were
included in this study. Medicaid eligibility is based on modified adjusted gross income relative to
the federal poverty level (FPL). (CMS, 2017) Adults in West Virginia at 133% of the FPL are
automatically eligible for Medicaid coverage. The International Classification of DiseasesRevision 10 (ICD-10) was used to assess IDU within this population, as well as comorbid
conditions relating to IDU. The time period for this study was chosen because the state Medicaid
expansion coverage under the Affordable Care Act (ACA) began January 1, 2014. Any
individuals under the age of 18 were excluded from these analyses.
3.2 Measures
The classification of IDU and associated comorbid conditions were based on a
predetermined list of ICD-9 and 10 codes. Both ICD-9 and 10 codes were used because WV
switch from ICD-9 to -10 in 2015. Since few, if any, ICD-9 or 10 codes relate specifically to
IDU and infections arising from IDU, a previously established framework was used to define
these measures in this study. (Tookes et al., 2015) This framework defines IDU and related
infections as having one or more drug abuse diagnoses with one or more infection diagnoses.
Table 1 outlines ICD-9 and 10 codes used to determine drug abuse. Table 2 lists ICD-9 and 10
codes used to determine IDU-related infections. Overdoses (OD) were defined according to the
drug-specific poisoning ICD-10 code.
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Clinical conditions, e.g HIV, acute HCV infection, and endocarditis, were defined using
indicator variables. Variables race and county of residence were collapsed into smaller categories
to avoid small cell counts. Race was collapsed into black, white, other, and unknown, with other
referring to Hispanic or native American/native Alaskan. A person’s county of residence was
collapsed into public health district, which was defined by surveillance reports conducted by the
West Virginia Department of Health and Human Resources (WV DHHR). Figure 1 provides a
graph of these public health districts.
Figure 1: West Virginia public health districts according to WV DHHR surveillance reports
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Table 1: ICD-9 and 10 codes used to define drug abuse
Drug Abuse
Diagnoses

ICD-9 Codes

ICD-10 Codes

Opiates

E850.0; E850.2; 304.00-.03; 304.70-.73; 305.50-.53;
965.01; 965.09

F11.20-.21; F19.20-.21; F11.10; T40.1X1A.1X4A; T40.2X1A-.2X4A

Cocaine

304.21-.23; 305.60-.63; 970.81

F14.20-.21; F14.10; T40.5X1A-.5X4A;

Amphetamines

304.41-.43; 305.71-.73; 969.72

F15.20-.21; F15.10; T43.621A-.624A

Sedatives

305.40-.43

F13.10

Other1

304.60-.63; 304.80-.83; 304.90-.93; 305.90-.93;
648.33; 648.34

F19.20-.21; F18.10; 099.321-.323; 099.325

1

’Other’ includes unspecified drug dependence, combination of drug dependence, and drug dependence relating to pregnant women.
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Table 2: ICD-9 and 10 codes used to define IDU-related infections
Infection
Diagnoses

ICD-9 Codes

ICD-10 Codes

Endocarditis

112.81; 421.0; 421.1; 421.9; 424.0-.3; 424.90; 424.91;
424.99

B37.6; I33.0; I39; I33.9; I34.0; I34.8; I35.0 -.2;
I35.8; I35.9; I36.0; I36.8; I37.0; I37.8; I38; I39

Sepsis or
bacteremia

038.0; 038.10-.12; 038.19; 038.2; 038.3; 038.40-.44;
038.49; 038.8; 038.9; 415.12; 422.92; 449; 785.52;
790.7; 995.90-.92

Osteomyelitis

730.00-.29; 730.90-.99

A40.9; A41.2; A41.01-.02; A41.1; A40.3; A41.4;
A41.50; A41.3; A41.51-.53; A41.59; A41.89;
A41.9; I26.90; I40.0; I76; R65.21; R78.81; R65.10;
R65.20
M86.10; M86.20; M86.119; M86.219; M86.129;
M86.229; M86.139; M86.239; M86.149; M86.249;
M86.159; M86.259; M86.169; M86.269; M86.179;
M86.279; M86.18; M86.28; M86.19; M86.29;
M86.60; M86.619; M86.629; M86.639; M86.642;
M86.659; M86.669; M86.679; M86.68; M86.69;
M86.9; M46.20; M46.30

Skin or soft tissue
infections

040.0; 324.0; 324.1; 324.9; 326; 567.22; 567.31;
567.38; 569.5; 572.0; 590.1; 681.00-.02; 681.10;
681.11; 681.9; 682.0-.9; 709.8; 728.86; 723.6; 729.30;
729.39; 785.4

A48.0; G06.0-.2; G09; K65.1; K68.12; K68.19;
K63.0; K75.0; N10; L03.019; L03.029; L03.019;
L03.039; L03.049; L03.019; L03.029; L03.39;
L03.49; K12.2; L03.211; L03.212; L03.213;
L03.221; L03.222; L03.319; L03.129; L03.317;
L03.811; L03.818; L03.891; L03.898; L03.90;
L03.91; L94.2; L98.8; M72.6; M54.02; M79.3; I96

HIV/AIDS

042; 079.53; 795.71; V08

B20; Z21; Z20.6

Hepatitis C, Acute

070.51; 070.41

B17.10; B17.11

Hepatitis B, Acute

070.21; 070.20; 070.30

B16.9; B16.1; B16.0

28

3.3 Design
This study was a retrospective, secondary data analysis of payer information collected on
West Virginia Medicaid participants between the fiscal years 2014 and 2016. Requested
variables included demographic characteristics, services rendered, and the cost of those services.
Demographic variables included age, gender, race/ethnicity, and county of residence. Service
variables included provider/facility type, claim type, service category, and the date the service
was provided. Cost variables included prescription, and medical service costs. Data were housed
on a secure drive with restricted access. West Virginia University’s Institutional Review Board
approved the protocol for this study.
3.4 Procedure
The data for this study was formally requested through the West Virginia Department of
Health and Human Resources’ external analytic request mechanism. The data request was based
on a pre-determined list of ICD codes which related to IDU, e.g. HCV, HIV, HBV, soft tissue
infections, ODs, etc. The cost of these data was $6,450. Specific protections were employed for
these data, and included access restrictions and storage on secure drives. Upon receiving the
requested data, preprocessing techniques were used to clean and merge data into workable
datasets. Data analysis followed in accordance with the aims and objectives of this study.
3.5 Outcomes
The underlying goal of this dissertation project was to determine specific service
utilization and associated costs, describe health outcomes, and develop a comprehensive profile
of PWID in WV using statewide, individual service-level data. The outcomes for the project
were: 1. determining the viability of state Medicaid data as a source of identifying drug
29

overdoses and drug-related infections by comparing to surveillance data using equivalence
testing; 2. understanding the service utilization patterns and potential associations with certain
characteristics of PWID; 3. estimating the cost attributable to specific services. Topics
investigated under each of these outcomes included: overdoses, viral infections, soft tissue
infections, geographic distributions, most common services accessed, and most costly services
accessed.
3.6 Statistical Analysis
Categorical variables, e.g. race, gender, service type, and clinical diagnoses, were
described using frequency and contingency tables with counts and percentages. Spatial variables,
e.g. county of residence and provider, were plotted using Geographic Information Systems (GIS)
packages (‘tmap’ and ‘rgdal’) in R to assess the distribution of PWID insured by Medicaid
within WV. Continuous variables, e.g. age, medical claims cost, and prescription claims cost,
were summarized using mean, median, minimum, maximum, interquartile range, and skew.
Scatterplots and histograms were utilized in order to visualize these continuous data to identify
potential outlying subjects or clusters, and to assess skew.
Given the size of claims data for a statewide population, asymptotic statistical tests, e.g.
χ2 test, were used to assess relationships among the categorical variables (e.g. race and service
types) to assess unadjusted relationships. Where there were small cell sizes (< 5), Fisher’s exact
test replaced the χ2 test. Pearson’s correlation coefficient was used to assess the relationship
between continuous variables, e.g. age versus medical claims cost. In the multivariate data
analysis, linear regression models were used for continuous outcome variables, logistic
regression models were used for binary outcome variables and ordinal logistic regression models
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were used for the ordinal scale outcome variables. P-values were used to comment on the
strength of the association.
For all formal hypothesis testing and confidence interval construction, an alpha-level of
0.05 was used. All analyses will be conducted using R version 3.3.3.
3.6.1 Analyses for Specific Aim 1:
Aim 1: Determine the efficacy of state Medicaid data as a proxy for disease surveillance data in
estimating the number of drug overdoses and injection drug related infections in WV between
2014 and 2016.
The prevalence of IDU and correlates were calculated using the requested ICD-9 and 10
codes. In order to determine if Medicaid claims data can be used as a proxy for measuring IDU
and associated infections in West Virginia (WV), calculated rates and/or proportions were
compared to state estimates obtained from various surveillance data. The full Medicaid claims
dataset, rather than the IDU subset, was used since IDU is only one of the risk behaviors for
HIV, HCV, and HBV. Medicaid claims utility, as a proxy to surveillance data, was assessed
using equivalency testing between the two data sources. Specifically, tests for equivalency
between Medicaid claims and surveillance data (gold standard) with an equivalence margin of
+/- 50% change relative to state surveillance rates served as the basis for determining the
viability of Medicaid claims data in estimating IDU. Since there is little information to support a
specific equivalence margin for rare events, the choice to use relative percent change for an
equivalence margin is loosely based on the CDC’s use of statistically significant changes in
heroin OD rates between calendar years. Table 3 reports the rates of each diagnosis according to
state surveillance data, and the corresponding equivalence margin.
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Table 3: Rates of injection drug use (IDU) related diagnoses obtained from 2015 state
surveillance reports with equivalence margin of +/- 50% relative change.
State Surveillance

Equivalence
Margin
Diagnoses
n
Rate per 100,000
+/- 50%
Hepatitis C, acute
63
3.4
(1.7, 5.1)
Hepatitis B, acute
272
14.7
(7.4, 22.1)
Persons Living with HIV/AID 1,988
107.8
(53.9, 161.7)
Heroin Poisoning
327
17.7
(8.9, 26.6)
a
Sources: West Virginia Department of Health and Human Resources; WV Poison Center
Annual Report
3.6.2 Analyses for Specific Aim 2
Aim 2: Examine service utilization and characteristics of WV Medicaid beneficiaries who inject
drugs between 2014 and 2016.
Service utilization was described according to inpatient, emergency room, and substance
abuse/mental health services. Observations were categorized based on frequency of service
utilization, with cut points indicating low, medium and high frequency usage. Cut points were
based on previous studies investigating emergency room, inpatient, and substance abuse service
utilization. (Lin, Bharel, Zhang, O'Connell, & Clark, 2015) For inpatient services, cut points at
one service, two services, and three or more services accessed during the study period were used.
For both emergency room and mental health/substance abuse services, cut points were at one to
two services, three to five services, and six or more services. Since the outcome variable is
naturally ordered, ordinal logistic regression was used to assess the relationship between patient
characteristics, e.g. demographics, diagnoses, and district of residence, and frequency of service
usage. The proportional odds assumption was assessed graphically.
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3.6.3 Analyses for Specific Aim 3
Aim 3: Examine the cost of service utilization of WV Medicaid beneficiaries who inject drugs
between 2014 and 2016.
Linear modelling of total costs for care and services was used to assess relationships with
patient characteristics, e.g. demographics, diagnoses, service types, and district of residence.
Two models were built, including one with an outcome variable of the total cost for medical
services only, and one with an outcome variable of the total cost for medical services and
prescription drugs. In both models, histograms of the outcome variables showed heavy right
skew. Subsequently, the outcome variables were log transformed to satisfy distributional
assumptions of multiple regression. Diagnostic plots, e.g. residual and Q-Q plots, were used to
assess any other assumption violations. Stepwise model selection with AIC was used to obtain
the final models. Adjusted effects were obtained from the final models to determine the highest
costs according to patient characteristics. These effects were back transformed to allow for
interpretation in terms of percent change relative to the reference group.
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CHAPTER 4: RESULTS

4.1 Description of Sample
Table 3 describes characteristics of the sample. There were 5,082 WV Medicaid
beneficiaries identified as PWID, utilizing 14,414 services between fiscal years 2014 and 2016.
Of these individuals, men comprised 51.6% (n=2,622) of the sample, while women accounted
for 48.3% (n=2,457). White race was the most common reported (60.5%; n=3,075), followed by
‘other’ (4.6%; n=236), and black (1.9%; n=98). A large number of individuals’ race was reported
as unknown (32.9%; n= 1,673). The median age was 34 years (18 – 85 years), and the majority
of persons had a plan type of fee-for-service (75.5%; n=3,822). The median total cost per person
attributable to medical claims and prescription claims was $794.90 ($0.00 – $203,800), and
$986.60 ($0.00 - $158,000) respectively. The median number of total services accessed per
person was four (1 – 84), and the median number of total prescriptions per person was 28 (1 –
616). Most individuals resided in District 2 (23.6%; n=1,197) and District 3 (20.7%; n=1,052)
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Table 4: Characteristics of West Virginia (WV) Medicaid beneficiaries who inject drugs
(n=5,082), 2014-2016
Characteristic
Gender
Men
Women
Race
Black
White
Other
Unknown
Claim Plan Type
Managed Care
Non Managed Care/Fee for
Service
District
District 1
District 2
District 3
District 4
District 5
District 6
District 7
District 8
Total

n(%)
2,622 (51.6)
2,457 (48.3)
98 (1.9)
3,075 (60.5)
236 (4.6)
1,673 (32.9)
1,247 (24.5)
3,835 (75.5)

734 (14.4)
1,197 (23.6)
1,052 (20.7)
275 (5.4)
288 (5.7)
332 (15.9)
558 (11.0)
640 (12.6)
5,082
Median (min – max)
Age
34 (18 – 85)
Medical Claims Cost
$794.90 ($0.00 – $203,800)
Prescription Claims Cost
$986.60 ($0.00 - $158,000)
Number of Services Accessed
6 (1 – 88)
Number of Prescriptions
28 (1 – 616)
1
Totals may not sum to 5,082 as a result of missing data.
2
Other race defined as Hispanic or American Indian/Alaska Native

Table 4 shows the geographic distribution of Medicaid insured PWID by WV county
during the study period. Since these data are based on fiscal years, July – December is included
for 2014, all of 2015 is included, and January – June is included for 2016. Kanawha county was
the most commonly reported county of residence (n=770; 2014-2016), followed by Cabell
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(n=651; 2014-2016) and Berkeley (n=361; 2014-2016). Figure 2 provides a visual representation
of the distribution of Medicaid insured PWID within WV.
Table 5: Number of WV Medicaid beneficiaries who inject drugs by county of residence, 20142016
County
2014
2015
2016
County
Barbour
Mineral
9
8
3
Berkeley
Mingo
84
217
79
Boone
Monongalia
39
43
10
Braxton
Monroe
7
10
6
Brooke
Morgan
12
26
6
Cabell
Nicholas
175
360
140
Calhoun
Ohio
2
5
1
Clay
Pendleton
6
10
4
Doddridge 2
Pleasants
5
0
Fayette
Pocahontas
32
70
19
Gilmer
Preston
2
3
0
Grant
Putnam
5
6
2
Greenbrier 15
Raleigh
36
11
Hampshire 11
Randolph
14
7
Hancock
Ritchie
38
51
17
Hardy
Roane
5
6
4
Harrison
Summers
39
59
15
Jackson
Taylor
12
25
8
Jefferson
Tucker
39
68
18
Kanawha
Tyler
250
421
141
Lewis
Upshur
8
9
3
Lincoln
Wayne
32
49
17
Logan
Webster
56
57
26
Marion
Wetzel
31
40
19
Marshall
Wirt
14
17
6
Mason
Wood
28
49
13
McDowell 18
Wyoming
50
6
Mercer
TOTAL
77
130
42
1
Totals may not sum to 5,082 as a result of missing data.
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2014
12
21
44
1
3
15
42
0
1
4
13
42
100
21
1
4
15
4
2
2
9
27
2
9
2
44
31

2015
20
33
76
7
27
24
53
5
2
4
26
59
149
31
5
12
23
11
1
9
14
67
6
7
1
111
27
5,0791

2016
2
13
25
1
5
6
28
1
1
1
10
27
45
12
1
3
5
2
0
0
2
34
7
6
4
32
7

Figure 2: Map of total number of WV Medicaid beneficiaries who inject drugs by county, 2015

The most common types of services accessed and patient diagnoses can be seen in Tables
6 and 7. ‘Physician Non-Specialty Inpatient’ services had the most patient visits with 2,957 over
the study period, followed by ‘Facility Inpatient Medical’ (n=2,783), ‘Facility Outpatient ER’
(n=2,099), and ‘Physician Non-Specialty ER’ (n=1,315). The most common diagnoses within
this sample included ‘Toxic Effects of Substances’ (n=5,077), ‘Infections of the Skin or
Subcutaneous Tissue’ (n=4,127), ‘Mental Health- Substance Abuse’ (n=2,030), and ‘Hepatitis,
Viral’ (n=1,302).
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Table 6: Ten most common service categories by number of patient visits among WV Medicaid
beneficiaries who inject drugs, 2014 - 2016
Service Category
Physician Non-Specialty Inpatient
Facility Inpatient Medical
Facility Outpatient ER
Physician Non-Specialty ER
Substance Abuse Other Outpatient
Physician Non-Specialty Office
Visits
Physician Specialty ER
Substance Abuse Office Visits
Professional Diagnostic Services
Laboratory Outpatient Other
Total

Patient Visits
2,957
2,783
2,099
1,315
772
505
499
482
433
422
12,267

Table 7: Ten most common diagnoses among WV Medicaid beneficiaries who inject drugs,
2014 – 2016.
Diagnoses
Toxic Effects of Substances
Infections/Inflammation - Skin/Subcutaneous
Tissue
Infections, NEC
Mental Health - Substance Abuse
Hepatitis, Viral
Cardiovascular Disorder, NEC
Pregnancy without Delivery
Signs/Symptoms/Other Cond, NEC
Infections - Musculoskeletal
Mental Health - Depression
Total

n
5,077
4,127
2,141
2,030
1,302
735
561
520
457
432
17,382

4.2 Specific Aim Results
4.2.1 Specific Aim 1
Aim 1: Determine the efficacy of state Medicaid data as a proxy for disease surveillance data in
estimating the number of drug overdoses and injection drug related infections in WV between
2014 and 2016.
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Rates per 100,000 people for all Medicaid beneficiaries are compared to state
surveillance reported rates in Table 8. According to Medicaid claims data, 739 beneficiaries had
an acute HCV diagnosis, 420 had an acute HBV diagnosis, 229 had an HIV/AIDS diagnosis, and
835 had a heroin poisoning in 2015. The year 2015 was used for these comparisons since it is the
only year within the data that includes an entire calendar year. The denominator for the incidence
rates among Medicaid beneficiaries was defined based on the estimate that Medicaid covers
approximately 29% of WV. (Foundation, 2017) For each rate (e.g. acute HCV, acute HBV, HIV,
and heroin OD), Medicaid claims data were significantly different from state surveillance data at
the alpha level of 0.05.
Table 8: Injection drug use (IDU) related diagnoses among all WV Medicaid beneficiaries in
2015 compared to incidence reported by surveillance data.
State Surveillance2

Medicaid Beneficiaries
Diagnosis

n

n

739

Rate per
100,0001
138.2

Hepatitis C, acute
Hepatitis B, acute
Persons living with
HIV/AIDS
Heroin Poisoning

420
229

78.5
42.8

272
14.7
1,988 107.8

838

156.1

327

63

Rate per
100,000
3.4

Test for
Equivalence4
p-value (95% CI)3
<0.001 (124.7,
144.8)
<0.001 (56.0, 71.6)
<0.001 (57.6, 72.4)

17.7

<0.001 (127.5,
149.3)
1
Denominator (534,760) equals 29% of West Virginians covered by Medicaid x 2015 population
(1,844,000).
2
Sources: West Virginia Department of Health and Human Resources; WV Poison Center
Annual Report
3
95% Confidence intervals are multiplied by 100,000 for interpretations
4
P-value < 0.05 implies there is significant difference in the comparison
4.2.2 Specific Aim 2
Aim 2: Examine service utilization and characteristics of WV Medicaid beneficiaries who inject
drugs between 2014 and 2016.
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Service utilization was described according to specific types of services, including
inpatient, mental health/substance abuse, and emergency room services.
Inpatient Services
Table 9 outlines characteristics of WV Medicaid beneficiaries who received an inpatient
service during the study period. Between 2014 and 2016, this sample of WV Medicaid
beneficiaries had 6,280 inpatient services. Among those who had an inpatient related service,
most were white (n=1,478; 61.3%) men (n=1,251; 51.9%), with a median age of 36 years.
Unknown race was frequently reported for this sample (n=776; 32.2%). The most common
clinical conditions were related to infections (n=2,889), and particularly soft tissue infections
(n=1,481). Toxic effects of substances were also a frequently reported clinical condition (n=689).
Most individuals with an inpatient service accessed one service during the study period
(n=1,354; 56.2%), while 401 (16.6%) had two, and 648 (26.9%) had three or more. Table 10
shows the adjusted associations between WV Medicaid beneficiary characteristics and the
frequency of inpatient service utilization obtained from an ordinal logistic regression model.
Individuals with endocarditis (aOR= 2.06, 95% CI= [1.58, 2.70]) and soft tissue infections
(aOR= 1.71, 95% CI= [1.42, 2.07]) had higher odds of utilizing more inpatient services
compared to those who did not. Acute HCV infection had a protective effect on having more
inpatient services (aOR= 0.59, 95% CI= [0.39, 0.88]).
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Table 9: Characteristics of WV Medicaid beneficiaries who received an inpatient service
between 2014 and 2016 (n=2,411).
n(%) 1
6,280

Characteristic
Total Number of Inpatient Visits
Gender
Men
Women
Race
African American
Other3
White
Unknown
Clinical Condition2
Skin/Subcutaneous Tissue Infection
Other Infections
Toxic Effect of Substances
Cardiovascular Disorder
Viral Hepatitis
District
District 1
District 2
District 3
District 4
District 5
District 6
District 7
District 8

1,251 (51.9)
1,159 (48.1)
57 (2.4)
99 (4.1)
1,478 (61.3)
776 (32.2)
1,481
1,408
689
401
231
334 (13.9)
521 (21.6)
536 (22.2)
164 (6.8)
146 (6.1)
145 (6.0)
295 (12.2)
269 (11.2)
Median (min – max)
36 (18 – 85)
1 (1 – 62)

Age (years)
Number of Encounters per Person
1
Totals may not add to 100% due to missing data
2
Clinical conditions based on duplicated dataset.
3
Other race defined as Hispanic or American Indian/Alaska Native
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Table 10: Adjusted associations between WV Medicaid beneficiary characteristics and inpatient
service utilization between 2014 and 2016.
Characteristic
Endocarditis Infection
No
Yes
Soft Tissue Infection
No
Yes
Acute Hepatitis C Infection
No
Yes
Age

aOR (95% CI)
Reference
2.06 (1.58, 2.70)
Reference
1.71 (1.42, 2.07)
Reference
0.59 (0.39, 0.88)
0.98 (0.97, 0.99)

Emergency Room Services
Table 11 summarizes the characteristics of WV Medicaid beneficiaries who inject drugs
and received an emergency room (ER) service during the study period. Most of these individuals
were white (n=1,290; 59.8%) men (n=1,159; 53.7%), with a median age of 33. The predominant
clinical condition was drug poisoning (n=2,280). Soft tissue infections were the next most
frequent (n=949), followed by other infections (n=113), viral hepatitis (n=59) and respiratory
disorders (n=58).
Among WV Medicaid beneficiaries who inject drugs and received an ER service, most
received one or two services during the study period (n=1,790; 83.0%), 327 (15.2%) received
three to five services, and 40 (1.9%) received six or more services. Table 12 contains the
adjusted relationships between patient characteristics and the frequency of ER service utilization.
Individuals with endocarditis (aOR= 2.60, 95% CI= [1.20, 5.26]), soft-tissue infections (aOR=
2.17, 95% CI= [1.48, 3.23]), or had a drug poisoning (aOR= 2.29, 95% CI= [1.62, 3.31]) had a
higher odds of presenting for more ER services compared to those who did not.
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Table 11: Characteristics of WV Medicaid beneficiaries who received an emergency room (ER)
service between 2014 and 2016 (n=2,157).
n(%) 1
3,913

Characteristic
Total Number of ER Visits
Gender
Men
Women
Race
African American
Other3
White
Unknown
Clinical Condition2
Toxic Effect of Substances
Skin/Subcutaneous Tissue Infection
Other Infections
Viral Hepatitis
Respiratory Disorder
District
District 1
District 2
District 3
District 4
District 5
District 6
District 7
District 8

1,159 (53.7)
996 (46.2)
45 (2.1)
122 (5.7)
1,290 (59.8)
700 (32.5)
2,280
949
113
59
58
216 (10.0)
620 (28.7)
462 (21.4)
69 (3.2)
133 (6.2)
144 (6.7)
198 (9.2)
311 (14.4)
Median (min – max)
33 (18 – 78)
1 (1 – 13)

Age (years)
Number of Encounters per Person
1
Totals may not add to 100% due to missing data
2
Clinical conditions based on duplicated dataset.
3
Other race defined as Hispanic or American Indian/Alaska Native
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Table 12: Adjusted associations between WV Medicaid beneficiary characteristics and
emergency room (ER) service utilization between 2014 and 2016.
Characteristic
Endocarditis Infection
No
Yes
Drug Poisoning
No
Yes
Soft Tissue Infection
No
Yes

aOR (95% CI)
Reference
2.60 (1.20, 5.26)
Reference
2.29 (1.62, 3.31)
Reference
2.17 (1.48, 3.23)

Mental Health and Substance Abuse Services
Table 13 highlights characteristics of WV Medicaid beneficiaries who inject drugs that
utilized mental health or substance abuse services between 2014 and 2016. White (n=488;
60.0%) men (n=413; 50.8%) had the most mental health or substance abuse services throughout
the study period. The median age for these individuals was 34 years. Substance abuse (n=1,572),
depression (n=262), bipolar disorder (n=109), other psychoses (n=53) and anxiety disorder
(n=42) were the most frequently reported clinical conditions.
The majority of individuals who utilized mental health or substance abuse services had
one or two service encounters during the study period (n=649; 80%). Comparatively, 119 (15%)
had three to five encounters, and 45 (6%) had six or more encounters. Unadjusted and adjusted
associations between patient characteristics and mental health and substance abuse service usage
were explored, but no statistically significant relationships were found at the 0.05 alpha level.
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Table 13: Characteristics of WV Medicaid beneficiaries who received a mental health and/or
substance abuse service between 2014 and 2016 (n=813).
n(%) 1
2,111

Characteristic
Total Number of Visits
Gender
Men
Women
Race
African American
Other3
White
Unknown
Clinical Condition2
Mental Health – Substance Abuse
Mental Health – Depression
Mental Health – Bipolar Disorder
Mental Health – Psychoses
Mental Health – Anxiety Disorder
District
District 1
District 2
District 3
District 4
District 5
District 6
District 7
District 8

413 (50.8)
399 (49.1)
6 (1.0)
63 (7.7)
488 (60.0)
255 (31.4)
1,572
262
109
53
42
171 (21.0)
189 (23.2)
138 (17.0)
37 (4.6)
48 (5.9)
61 (7.5)
71 (8.7)
97 (11.9)
Median (min – max)
34 (18 – 65)
1 (1 – 65)

Age (years)
Number of Encounters
1
Totals may not add to 100% due to missing data
2
Clinical conditions based on duplicated dataset.
3
Other race defined as Hispanic or American Indian/Alaska Native
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4.2.3 Specific Aim 3
Aim 3: Examine the cost of service utilization of WV Medicaid beneficiaries who inject drugs
between 2014 and 2016.

The total cost of medical services for this sample was $18,473,217, and the total cost for
prescriptions was $154,789,571. The most commonly accessed services for this sample and the
associated costs are listed in Table 14. Inpatient services incurred the highest cost for this sample
during the study period. Specifically, ‘Facility Inpatient Medical’ services accounted for
$14,390,988.00, nearly 18 times costlier than the next highest service type (Mental Health
Inpatient; $805,993.30). ‘Facility Outpatient ER’ ($779,515.90), ‘Facility Inpatient Long Term
Care’ ($656,044.90), and ‘Substance Abuse Inpatient’ ($420,346.50) also accounted for a large
proportion of the total costs for this sample.
Results from the multiple regression models are shown in Tables 15 and 16. In the first
model, where the outcome was the natural log of the cost for medical services, while controlling
for other covariates, men cost 16% more than women; individuals with endocarditis cost 18%
more than those without; individuals with acute HCV infection cost 16% more than those
without; individuals with acute HBV infection cost 53% more than those without; and
individuals residing in District 5 cost 84% more than those living in District 3 (reference). The
second model, in which the outcome was the natural log of the total cost of medical services and
prescription drugs per person, men cost less than women (24.6% decrease), while those with
HIV (281% increase) and endocarditis (48.5% increase) cost more than those not infected.
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Table 14: Commonly accessed services among WV Medicaid beneficiaries who inject drugs and
associated costs (2014-2016).
Service Type
Visits (n) Total Cost
Facility Inpatient Long Term Care 105
$656,044.90
Facility Inpatient Maternity
108
$241,074.40
Facility Inpatient Medical
2,783
$14,390,988.00
Facility Inpatient Non Acute
8
$10,746.44
Physician Specialty Inpatient
319
$38,169.89
Physician Non-Specialty Inpatient 2,957
$436,426.60
Inpatient Total1
6,280
$15,773,450.23
Facility Outpatient ER
2,099
$779,515.90
Physician Non-Specialty ER
1,315
$130,140.30
Physician Specialty ER
499
$59,833.30
Emergency Room Total
3,913
$969,489.50
Mental Health Inpatient
335
$805,993.30
Mental Health Office Visits
68
$4,375.71
Mental Health Other Outpatient
136
$24,845.67
Mental Health Total
539
$835,214.68
Substance Abuse Inpatient
318
$420,346.50
Substance Abuse Office Visits
482
$27,428.39
Substance Abuse Other Outpatient 772
$74,809.86
Substance Abuse Total
1,572
$522,584.75
TOTAL
12,304
$18,100,739.16
1
Not including Mental Health or Substance Abuse Inpatient services.
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Table 15: Relationships between characteristics of WV Medicaid beneficiaries who inject drugs
and the natural log of total cost per medical service encounter (US Dollars).
Characteristic

Coefficient (95%
CI)

% Change vs.
Reference

Service Type
Inpatient
Reference
Reference
Emergency
-1.12 (-1.20, -1.05)
-67.5%
Mental/Substance Abuse
-1.30 (-1.39, 1.20)
-72.6%
Other
-2.39 (-2.47, -2.31)
-90.8%
Age (years)
0.01 (0.01, 0.02)
1.5%
Gender
Women
Reference
Reference
Men
0.15 (0.10, 0.21)
16.9%
Race
White
Reference
Reference
Black
-0.16 (-0.36, 0.03)
-15.2%
1
Other
-0.13 (-0.25, 0.00)
-12.0%
Unknown
-0.11 (-0.17, -0.04)
-10.1%
District
District 3
Reference
Reference
District 1
0.29 (0.19, 0.38)
33.2%
District 2
0.19 (0.11, 0.28)
21.3%
District 4
0.27 (0.13, 0.41)
30.7%
District 5
0.61 0.48, 0.75)
84.7%
District 6
0.50 (0.37, 0.63)
65.2%
District 7
0.31 (0.21, 0.41)
36.4%
District 8
0.19 (0.09, 0.29)
21.3%
Endocarditis Infection
No
Reference
Reference
Yes
0.17 (0.06, 0.27)
18.1%
Acute HBV Infection
No
Reference
Reference
Yes
0.53 (0.39, 0.66)
69.0%
2
Adjusted R =0.2379
1
Other race defined as Hispanic and American Indian/Alaska Native
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Table 16: Relationships between characteristics of WV Medicaid beneficiaries who inject drugs
and the natural log of the combined total cost of medical services and prescription drugs per
person (US Dollars).
Characteristic
Service Type
Inpatient
Emergency
Mental/Substance Abuse
Other
Age (years)
Gender
Women
Men
Endocarditis Infection
No
Yes
HIV Infection
No
Yes
Adjusted R2=0.1861

Coefficient (95%
CI)

% Change vs.
Reference

Reference
-1.14 (-1.27, -1.01)
-0.22 (-0.38, -0.05)
-0.77 (-0.92, -0.63)
0.03 (0.02, 0.04)

Reference
-68.1%
-19.6%
-53.8%
3.1%

Reference
-0.28 (-0.39, -0.18)

Reference
-24.6%

Reference
0.40 (0.16, 0.63)

Reference
48.5%

Reference
1.34 (0.98, 1.69)

Reference
281.0%

49

CHAPTER 5: DISCUSSION

This dissertation had three primary aims. The first aim was to determine the efficacy of
state Medicaid data as a proxy for disease surveillance data in estimating the number of drug
overdoses and injection drug related infections in WV between 2014 and 2016. The prevalence
rates for HIV, acute HCV, acute HBV, and heroin overdoses (OD) according to West Virginia
(WV) Medicaid claims data are reported in Table 8. Each prevalence rate was significantly
different from state surveillance rates at the alpha level of 0.05. This result indicates that ICD
codes from a Medicaid claims database are not a suitable proxy for state surveillance. The likely
reason for the large discrepancy between these data sources with regards to acute HCV, acute
HBV, and HIV is the inability to determine whether the case is new with ICD codes.
Consequently, the prevalence rates as determined by Medicaid claims data were likely
overestimations. As for heroin ODs, the Poison Control Center monitors OD rates that are
reported to it passively. However, reporting heroin ODs is not mandated in WV, as it is with new
cases of acute HCV, acute HBV, and HIV. Therefore, it is possible that the heroin OD
prevalence rate from the Poison Control Center is an underestimation of the true rate. Similarly,
the heroin OD rate from Medicaid claims data is also possibly underestimating the prevalence
since not every person who injects drugs (PWID) is insured by Medicaid. (Tookes et al., 2015)
The second aim of this dissertation project was to describe service utilization among WV
Medicaid beneficiaries who inject drugs. Three service types were specifically investigated for
this project, including inpatient, emergency room (ER), and mental health and substance abuse
services.
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Of the service types, inpatient services were the most frequently utilized with 2,411
people accumulating 6,280 visits between July 2014 and June 2016. The southern part of WV,
including Districts 1 (13.9%), 2 (21.6%), and 3 (22.2%) had the most individuals accessing
inpatient services. Comparable numbers of men (51.9%) and women (48.1%) utilized inpatient
services, while white race (61.3%) was the most frequently reported. Infectious diseases,
including soft tissue infections (n=1,481) and viral hepatitis (n=231), were the most common
conditions reported among those receiving inpatient services. When examining adjusted
relationships between patient characteristics and frequency of service utilization obtained via
ordinal logistic regression, infectious diseases again were consequential. Specifically, those with
endocarditis infection had a 2.06 times higher odds of receiving three or more inpatient services
during the study period compared to receiving two services or less. Similarly, individuals with a
soft tissue infection had a 1.71 times higher odds of receiving three or more inpatient services.
Infectious diseases, like endocarditis and soft tissue infections, are largely preventable through
the use of clean injecting equipment. Harm reduction strategies, like syringe exchange programs
(SEPs), have proven to be effective in reducing the incidence of these types of infectious
diseases by supplying clean injection equipment and other services. (Bastos & Strathdee, 2000;
Kwon et al., 2009; Moss & Munt, 2003; Vickerman et al., 2006; D. P. Wilson et al., 2015)
Reducing soft tissue and endocarditis infections, among others, could possibly reduce the use of
inpatient services, which are generally associated with higher costs. (Tookes et al., 2015)
ER services were the second most commonly accessed service type for this sample, with
2,157 people presenting to the ER 3,913 times during the study period. There were slightly more
men (53.7%) than women (46.2%), and white race (59.8%) was the most commonly reported
among those accessing ER services. Similar to inpatient services, the southern Districts 2
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(28.7%) and 3 (21.4%) had the largest number of individuals utilizing the ER. Similar to
previous studies, drug poisonings (n=2,280) accounted for the largest proportion of ER services
accessed, and were 2.4 times more frequent than the next clinical condition (soft tissue
infections; n=949). (Backmund, Schuetz, Meyer, Edlin, & Reimer, 2009) Adjusted associations
further showed that drug poisonings were associated with more frequent ER usage. Individuals
with a drug poisoning had a 2.29 times higher odds of having six or more ER services compared
to three to five services, and one to two services. Similar to inpatient services, endocarditis
(aOR= 2.60) and soft tissue infections (aOR= 2.17) were also associated with more ER service
usage. This study is in agreement with previous studies show that PWID tend to use the ER
frequently. (Fairbairn et al., 2012; Palepu et al., 2001) As with inpatient services, infectious
diseases were a large component of frequent ER service utilization within this sample. Increasing
access to preventative care for PWID may serve to reduce frequent service utilization, and
thereby reduce cost.
Mental health and substance abuse services were accessed 2,111 times by 813 WV
Medicaid beneficiaries who inject drugs during the study period. Approximately equal numbers
of men (50.8%) and women (49.1%) utilized mental health and substance abuse services, while
white race (60.0%) outweighed all others. As with inpatient and ER services, the southern
districts, including 1 (21.0%), 2 (23.2%), and 3 (17.0%), had the most individuals accessing
mental health and substance abuse services. Mental health conditions relating to substance abuse
(n=1,572), depression (n=262) and bipolar disorder (n=109) were the most commonly reported.
Adjusted relationships between patient characteristics and frequency of mental health and
substance abuse service usage were explored, but yielded no statistically significant relationships
at the alpha level of 0.05.
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The third aim of this dissertation project was to describe the cost of service utilization
among WV Medicaid beneficiaries who inject drugs. The total cost for medical services and
prescription drugs was $18,473,217 and $154,789,571, respectively. Similar to Aim 2, cost was
described according to inpatient, ER, and mental health and substance abuse services. Congruent
with current literature, inpatient services were the costliest. (Tookes et al., 2015) A total of 6,280
inpatient services during the study period accumulated $15,773,450.23 in charges. In other
words, inpatient services, not including mental health or substance abuse inpatient services,
accounted for 87% of the total cost for medical services accessed by this sample ($18,473,217)
during the entire study period. Also, mental health specific services had far fewer visits than any
other service type, yet cost a similar amount compared to ER and substance abuse services.
Two separate multiple regression models were constructed to examine the relationship
between patient characteristics and cost. The first included the natural log of cost for medical
services only, and the second included the natural log of cost for medical services and
prescription drugs. In the first model (medical costs only), while controlling for other covariates,
inpatient services were shown to cost significantly more than any other service type. Also, every
district cost significantly more than District 3 (reference). District 3 was chosen as the reference
because is the most populated area of WV. Infectious diseases, e.g. endocarditis (18.1%
increase), and acute HBV infection (69.0% increase), were also associated with higher service
costs. In the second model (medical and prescription costs), HIV infection was associated with
significantly large increase in cost. Individuals with HIV cost 281% more than their counterparts.
These results further support the need to increase access of preventative services, like SEPs and
vaccinations, to reduce morbidity and cost within the injection drug use (IDU) population. As
mentioned, many common infections among PWID are preventable given access and subsequent
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utilization of these services, and the cost of providing such services is cost effective. Further,
while HIV infection is associated with multiple risk behaviors other than IDU, SEPs can serve to
reduce HIV risk among PWID. (D. P. Wilson et al., 2015) Model fit was assessed via
diagnostic plots, e.g. Q-Q normality plots and residuals plots, and it was determined that no
major assumption violations occurred. The adjusted R2 for the first model was 0.2379 and
0.1861 for the second.
5.1 Limitations
The goal of this dissertation project was to determine specific service utilization and
associated costs, describe health outcomes, and develop a comprehensive profile of PWID in
WV using statewide, individual service-level data. Few, if any studies, have investigated IDU at
the state level using this methodology. However, there were limitations to this project.
First, Medicaid claims data come from an administrative database, and are not directly
intended for research. Consequently, some variables did not contain an ideal level of
information, or had missing information. For instance, nearly 33% of individuals in this dataset
had an ‘unknown’ race reported. This likely affected the estimates obtained from various models,
and thus limited the interpretations. Also, this project’s methodology hinged on the use of ICD
codes to identify IDU and associated conditions. This is a limitation for various reasons,
including the tendency for ICD codes to underestimate prevalence of certain conditions. (G.
Jones et al., 2012) Also, while the framework for identifying IDU was based on a previous study
(Tookes et al., 2015), it is possible that misclassification on case status (IDU) occurred since it is
not possible to directly identify IDU with ICD codes. The study period for this project also
overlapped with the transition between ICD-9 and ICD-10 codes. While both were included in
the analysis, the cross-walk between revisions may not be 100%
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This study is also limited in that the project sample only included those who were insured
by Medicaid. Although Medicaid is the largest insurer for WV, and studies report that a large
number of PWID are covered by Medicaid, this study has limited generalizability outside of the
WV IDU Medicaid population. (Foundation, 2017; Takahashi et al., 2010; Tookes et al., 2015)
In addition, many PWID do not have insurance coverage, and possibly have different
characteristics compared to those who are insured.
For Specific Aim 2, ordinal logistic regression was used to determine relationships
between patient characteristics and frequent service usage. One of the underlying assumptions
for this type of model is the proportional odds assumption, or that the relationship between a
predictor and each level of the outcome variable are the same. Assessment of this assumption
showed that some variables were questionable, while others were appropriate. Violation of this
assumption would indicate that the effect of a variable is different according each level of the
outcome. This may warrant a different model, e.g. partial proportional odds model, which relaxes
the proportional odds assumption.
5.2 Future Research
Results from this project warrant further research. Given the results from Aim 1,
procedure codes, which identify specific surgical, medical, or diagnostic activities, may provide
more information to help identify new cases of acute HCV, acute HBV, and HIV in
administrative databases. If effective in identifying new cases, administrative data could provide
information on individuals who cross state lines for medical care, and in turn improve
surveillance for these conditions.
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Different statistical models for investigating the relationship between patient
characteristics and frequency of service utilization (Aim 2) are recommended. The partial
proportional odds model relaxes the limiting proportional odds assumption, but complicates
interpretations. Another method may be to treat frequency of service utilization as a count
variable, and employee negative binomial regression to explore relationships.
Medicaid data was used for this project because it is the largest insurer of WV and is
reportedly one of the largest insurers of PWID. However, generalizability to PWID who are not
covered by Medicaid is limited. Therefore, other data sources may be considered. Hospital
discharge data, for example, provide an array of information, including diagnosis codes,
procedure codes, cost, and demographics. Additionally, hospital discharge data includes
information on all-payer types. Using hospital discharge data may serve to improve external
validity.
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